Par Pharmaceutical Reports Fourth Quarter and Full Year 20...(p operations $ 0.16 ...),Health

operations $ 0.16 $0.15 $ 1.47 $ 0.19

Loss from discontinued

operations (Restated) (0.04) (0.03) (0.04) (0.03)

Net income (Restated) $ 0.12 $0.12 $ 1.43 $0.16

Weighted average number of

common shares outstanding:

Basic 33,944 34,484 34,494 34,422

Diluted 34,026 34,703 34,718 34,653

Reconciliation Between Reported (GAAP) and Adjusted Income

from Continuing Operations

(In thousands, except per share data)

(Unaudited)

Three Months Ended

Dec. 31, Dec. 31,

2007 2006

Income from Continuing Operations $5,529 $5,045

Stock Option Tender Offer 4,615 -

Investment Gain (3,059) (3,190)

Severance Costs - 5,229

Asset Impairment - 1,000

Estimated Tax on Adjustments (591) (1,185)

Adjusted Income from Continuing

Operations (non-GAAP measure) $6,494 $6,899

Diluted Earnings Per Share from

Continuing Operations:

Reported $0.16 $0.15

Adjusted (non-GAAP measure) $0.19 $0.20

Twelve Months Ended

Dec. 31, Dec. 31,

2007 2006

Income from Continuing Operations $51,110 $6,741

Gain on Sales of Product Rig
'/>"/>